TuHURA reports 2026 Q3 results and announces FDA clearance for Phase 1b study.
Management reported Q3 2026 financial results and a $50 million credit facility. Additionally, the FDA granted clearance to initiate a Phase 1b study of TBS-2025 for r/r NPM1 AML.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
START FREE — 10,000 calls/day, no key needed